MIST
Price
$2.25
Change
+$0.07 (+3.23%)
Updated
Jul 8, 04:59 PM (EDT)
Capitalization
120.29M
28 days until earnings call
NERV
Price
$1.63
Change
-$0.01 (-0.61%)
Updated
Jul 8 closing price
Capitalization
11.4M
34 days until earnings call
Interact to see
Advertisement

MIST vs NERV

Header iconMIST vs NERV Comparison
Open Charts MIST vs NERVBanner chart's image
Milestone Pharmaceuticals
Price$2.25
Change+$0.07 (+3.23%)
Volume$5.16K
Capitalization120.29M
Minerva Neurosciences
Price$1.63
Change-$0.01 (-0.61%)
Volume$5.82K
Capitalization11.4M
MIST vs NERV Comparison Chart in %
Loading...
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MIST vs. NERV commentary
Jul 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MIST is a StrongBuy and NERV is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 09, 2025
Stock price -- (MIST: $2.25 vs. NERV: $1.63)
Brand notoriety: MIST and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MIST: 147% vs. NERV: 61%
Market capitalization -- MIST: $120.29M vs. NERV: $11.4M
MIST [@Biotechnology] is valued at $120.29M. NERV’s [@Biotechnology] market capitalization is $11.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $309.49B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MIST’s FA Score shows that 0 FA rating(s) are green whileNERV’s FA Score has 0 green FA rating(s).

  • MIST’s FA Score: 0 green, 5 red.
  • NERV’s FA Score: 0 green, 5 red.
According to our system of comparison, both MIST and NERV are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MIST’s TA Score shows that 4 TA indicator(s) are bullish while NERV’s TA Score has 4 bullish TA indicator(s).

  • MIST’s TA Score: 4 bullish, 4 bearish.
  • NERV’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MIST is a better buy in the short-term than NERV.

Price Growth

MIST (@Biotechnology) experienced а +19.68% price change this week, while NERV (@Biotechnology) price change was -2.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.39%. For the same industry, the average monthly price growth was +14.41%, and the average quarterly price growth was +12.94%.

Reported Earning Dates

MIST is expected to report earnings on Nov 12, 2025.

NERV is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+9.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MIST($120M) has a higher market cap than NERV($11.4M). MIST YTD gains are higher at: -4.661 vs. NERV (-26.629). NERV has higher annual earnings (EBITDA): 8.58M vs. MIST (-48.18M). MIST has more cash in the bank: 56M vs. NERV (17.3M). NERV has less debt than MIST: NERV (0) vs MIST (55.6M). MIST (0) and NERV (0) have equivalent revenues.
MISTNERVMIST / NERV
Capitalization120M11.4M1,053%
EBITDA-48.18M8.58M-561%
Gain YTD-4.661-26.62918%
P/E RatioN/A1.99-
Revenue00-
Total Cash56M17.3M324%
Total Debt55.6M0-
FUNDAMENTALS RATINGS
MIST vs NERV: Fundamental Ratings
MIST
NERV
OUTLOOK RATING
1..100
2459
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3564
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
9550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (40) in the Biotechnology industry is in the same range as MIST (55) in the Pharmaceuticals Major industry. This means that NERV’s stock grew similarly to MIST’s over the last 12 months.

NERV's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that NERV’s stock grew similarly to MIST’s over the last 12 months.

NERV's SMR Rating (100) in the Biotechnology industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that NERV’s stock grew similarly to MIST’s over the last 12 months.

MIST's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as NERV (64) in the Biotechnology industry. This means that MIST’s stock grew similarly to NERV’s over the last 12 months.

NERV's P/E Growth Rating (99) in the Biotechnology industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that NERV’s stock grew similarly to MIST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MISTNERV
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
N/A
Declines
ODDS (%)
Bearish Trend 19 days ago
84%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
81%
Aroon
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IIJIF20.41N/A
N/A
Internet Initiative Japan, Inc.
NCBDF34.09N/A
N/A
Bandai Namco Holdings, Inc.
PVARF10.57N/A
N/A
Porvair PLC
EMPPF0.17N/A
N/A
EMP Metals Corp.
FNMCF0.30-0.02
-5.29%
FIRST NORDIC METALS CORP.